Relay Therapeutics (RLAY)

Relay’s discovery engine, known as the Dynamo platform, combines computational modeling, structural biology, biophysics, chemistry, and experimental biology. By studying how proteins move and change shape, the platform aims to improve the design of small-molecule drug candidates with greater selectivity and therapeutic potential. The company applies this technology to targets where existing medicines may be limited by resistance, toxicity, or insufficient precision.

Its pipeline includes programs in precision oncology and genetic disease. Candidates referenced by the company include RLY-2608, RLY-4008, RLY-8186, and additional preclinical or clinical-stage assets. These programs are designed to address molecularly defined patient populations, a common feature of modern targeted cancer therapy. In oncology, Relay’s work is aligned with a broader industry trend toward treatments selected by tumour genetics and pathway dependencies.

As a clinical-stage company, Relay does not operate like a commercial drug manufacturer with a broad marketed product portfolio. Its value is tied to research execution, clinical trial progress, regulatory outcomes, and the ability to advance or partner drug candidates. The company represents a technology-driven model of drug discovery that seeks to translate protein motion into new therapeutic options.